Atea Pharmaceuticals, Inc. - common stock (AVIR)

CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.

This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.

Atea Pharma (AVIR) Earnings Call Transcript

Atea Pharmaceuticals reports Q3 2025 financials, focusing on its advancing Phase 3 HCV program and pipeline expansion into hepatitis E virus (HEV).

Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics.

Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug.

Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuvir and ruzasvir.

Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy.

Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resistance risk.

AVIR stock results show that Atea Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.

A look at five low-priced stocks with lots of cash per share, and no or very low debt. Most of them have very low-cap stocks and should be considered very speculative.

Atea Pharmaceuticals Inc (NASDAQ: AVIR) reported initial data from the first 52 patients in the lead-in cohort of its Phase 2 combination eight-week study of bemnifosbuvir and ruzasvir (RZR) for

Gainers QualTek Services Inc. (NASDAQ: QTEK) shares jumped 127.2% to $0.1740 after dropping around 21% on Friday. Qualtek Services recently filed voluntarily petitions for Chapter 11 bankruptcy.